GLP-1 INTELLIGENCE
LIVEStay ahead of the GLP-1 market.
Clinical research, industry moves, and regulatory shifts — curated from the sources that matter. Updated hourly.
14 articles
Opinion: Telehealth abortion with mifepristone continues, with backup plans still in place
Restricting telehealth prescribing of mifepristone wouldn't spell the end of telehealth medication abortion, writes OB-GYN Christine Henneberg.
Can Precision Psychiatry Be Delivered Remotely? The Limits and Opportunities of Telehealth in Interventional Care
How much of precision interventional psychiatry can actually happen remotely, and where does the model hit a wall? The answer is potentially more nuanced than the conventional framing suggests. The post Can Precision Psychiatry Be Delivered Remotely? The Limits and Opportunities
Lead Defendants in the IM Mastery Academy MLM Scheme to Turn Over Tens of Millions of Dollars in Assets to Settle FTC Charges
FTC alleged Chris and Isis Terry and their companies used false or baseless earnings claims to promote their training services and MLM venture The Federal Trade Commission and State of Nevada will require five individual and corporate IM Mastery Academy defendants, including ring
Shutterstock to Pay $35 Million to Settle FTC Allegations Over Illegal Subscription and Cancellation Practices
Online licensing platform allegedly charged consumers without their consent, failed to disclose auto-renewals and cancellation charges, and made cancelling difficult Shutterstock Inc. will pay $35 million to settle Federal Trade Commission allegations that the online digital phot
FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA
FDA continues to implement its bold food agenda, with two decisive actions focused on food chemical safety.
FDA Advances Drug Repurposing to Address Unmet Medical Needs
FDA announced it is soliciting input on efforts with respect to drug repurposing to help address unmet medical needs across a range of diseases and conditions.
FTC Chairman Ferguson Advises Companies to Comply with the Take It Down Act
Federal Trade Commission Chairman Andrew N. Ferguson sent letters today to more than a dozen prominent technology companies reminding businesses of their obligation to comply fully with the Take It Down Act (TIDA) no later than May 19. Signed into law last year by President Donal
FTC and Illinois Take Action to Stop Deceptive Conduct by Company that Created Thousands of Business Listings of Fake Local Home Repair Businesses
Premium Home Service also used fake online reviews to boost ratings and siphon customers from true local businesses The U.S. Department of Justice, on behalf of the Federal Trade Commission, and the state of Illinois sued Chicago-based company Premium Home Service (PHS) and its o
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.
FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
The U.S. Food and Drug Administration today issued a final guidance for industry, Postapproval Pregnancy Safety Studies, with recommendations on different methodologies that can be used in the postapproval setting to study the safety of drugs and biological products when used dur
FTC Chairman Ferguson Issues Noncompete Warning Letter to Mortgage Connect
Federal Trade Commission Chairman Andrew N.View Press Release
FTC Finalizes Consent Order in Valvoline-Greenbriar Deal
The Federal Trade Commission finalized a consent order resolving antitrust concerns related to a deal between Valvoline Inc. and private equity firm Greenbriar Equity Fund V., L.P. (Greenbriar). View Press Release
FDA Expands AI Capabilities and Completes Data Platform Consolidation
FDA announced major steps in its bold initiative to modernize the agency. The agency launched Elsa 4.0, a significant upgrade to the agency’s internal AI tool available to all FDA staff, from scientific reviewers to investigators.
FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
FDA announced that it is piloting one-day inspectional assessments, as part of a broader initiative to make its inspectional resources more targeted and efficient.
Ready to build your GLP-1 program?
NexaCare handles the operational layer so your clinic can focus on patient outcomes.
Book a Demo →